Results 21 to 30 of about 5,967 (167)
Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers
European Thyroid Journal, 2023 Objective: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors ...
Markus Eszlinger +9 more
doaj +1 more source
Primary and Metastatic Melanoma With NTRK Fusions [PDF]
American Journal of Surgical Pathology, 2018 A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide potential therapeutic targets for malignant lesions. Various translocations, such as those involving the anaplastic lymphoma kinase (ALK), neurotrophic tropomyosin receptor kinase 1 (NTRK1), and ...
Cecilia, Lezcano +4 more
openaire +2 more sources
PLoS ONE, 2022 The clinical profiles and outcomes of patients with neurotrophic tropomyosin receptor kinase fusion-positive (NTRK+) solid tumors receiving standard of care other than tropomyosin receptor kinase inhibitor (TRKi) targeted therapy have not been well ...
Derrek P Hibar +6 more
doaj +1 more source
Human Pathology Reports, 2022 Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers found in a few rare tumours. However, NTRK rearrangements are being increasingly identified in a range of soft tissue neoplasms. Recognition of NTRK fusion-driven sarcomas is
Vanessa Young +3 more
doaj +1 more source
Identifying patients with NTRK fusion cancer [PDF]
Annals of Oncology, 2019 Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer.
Solomon, J P +3 more
openaire +3 more sources
Clinicopathologic and molecular spectrum of gastrointestinal stromal tumor (GIST) with NTRK fusion and marked response to larotrectinib in GIST with NTRK fusion: a case report. [PDF]
Cell Oncol (Dordr)Abstract Purpose This study aimed to characterize the clinicopathological, immunophenotypic, and molecular features of gastrointestinal stromal tumors (GISTs) harboring NTRK fusions and to evaluate their diagnostic, prognostic, and therapeutic implications.
Shen Y +11 more
europepmc +3 more sources
Pediatric NTRK fusion sarcomas [PDF]
, 2020 Abstract Background While ETV6-NTRK3 fusion is common in infantile fibrosarcoma, NTRK1 fusion in pediatric sarcoma is extremely rare and consequently not well known. Herein, we evaluated NTRK1 fusion pediatric sarcomas to determine their clinicopathological nature and differential diagnosis from classic ETV6-NTRK3 fusion infantile fibrosarcoma.
Jeongwan Kang +9 more
openaire +1 more source
Identificación de genes de fusión NTRK. Experiencia en México
Gaceta Mexicana de Oncología, 2023 Objetivo: Evaluar la prevalencia de fusiones TRK en pacientes con cáncer en México. Material y métodos: En un estudio de tipo canasta, se determinó la presencia de genes de fusión NTRK, mediante inmunohistoquímica y secuenciación de nueva generación, en ...
Leticia Bornstein-Quevedo +4 more
doaj +1 more source
healthbook TIMES. Oncology Hematology, 2021 In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion.
Holger Moch +9 more
doaj +2 more sources
JTO Clinical and Research Reports, 2023 The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC.
Mary C. Boulanger, MD +4 more
doaj +1 more source